Discover Astex
R&D
Partnering
Our People & Culture
- Career Opportunities
Media
Contact
Search
Menu Menu

You are here: Home1 / Posters2 / 20123 / AACR: Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors...

AACR: Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors of MetAP2

24 October 2012/in 2012, Discovery

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2012-10-24 12:26:172016-11-24 12:58:12AACR: Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors of MetAP2

© Astex Pharmaceuticals
All rights reserved

Useful links

Home
Sitemap
Privacy Policy
Terms of Use
Legal

LinkedIn

Member of the Otsuka Group

Astex Pharmaceuticals Announces Initiation of AT13387 Phase 2 Study in Non-Small...2012 EORTC: Characterization of a Potent XIAP & cIAP1 Dual Antagonist in...

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok